These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25766836)

  • 1. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
    Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
    Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
    Lim JH; Jang S; Park CJ; Cho YU; Lee JH; Lee KH; Lee JO; Shin JY; Kim JI; Huh J; Seo EJ
    Cancer Genet; 2014; 207(1-2):40-5. PubMed ID: 24613277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
    Maesako Y; Izumi K; Okamori S; Takeoka K; Kishimori C; Okumura A; Honjo G; Akasaka T; Ohno H
    Int J Hematol; 2014 Feb; 99(2):202-7. PubMed ID: 24307515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.
    Maesako Y; Okumura A; Takeoka K; Kishimori C; Izumi K; Kamoda Y; Iioka F; Akasaka T; Ohno H
    Leukemia; 2014 Sep; 28(9):1935-7. PubMed ID: 24850290
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
    Katayama R; Shaw AT; Khan TM; Mino-Kenudson M; Solomon BJ; Halmos B; Jessop NA; Wain JC; Yeo AT; Benes C; Drew L; Saeh JC; Crosby K; Sequist LV; Iafrate AJ; Engelman JA
    Sci Transl Med; 2012 Feb; 4(120):120ra17. PubMed ID: 22277784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    Ma Z; Hill DA; Collins MH; Morris SW; Sumegi J; Zhou M; Zuppan C; Bridge JA
    Genes Chromosomes Cancer; 2003 May; 37(1):98-105. PubMed ID: 12661011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
    Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.
    Hayashi A; Tanoshima R; Tsujimoto SI; Yanagimachi M; Takeuchi M; Sasaki K; Ikeda J; Kajiwara R; Ito S; Takahashi H
    Blood Cancer J; 2016 Aug; 6(8):e456. PubMed ID: 27494825
    [No Abstract]   [Full Text] [Related]  

  • 15. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA
    N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.